BioNTech Results Presentation Deck
Pursuing Multiple Novel COVID-19 Vaccine Approaches to
Provide Durable and High-Level Protection against Evolving Variants
16
Next generation SARS-CoV-2 spike antigen
Engineered for optimized immunogenicity
Increase prefusion stability
Expose more neutralizing-sensitive epitopes
ā
ā
Long-term: Next-Generation Vaccine Approaches
T cell enhancing vaccine candidate
Designed to stimulate and enhance
T cell immunity
BNT162b5: bivalent vaccine candidate
Enhanced SARS-CoV-2 spike protein of
ancestral strain and Omicron BA.2 sublineage
Phase 2:
FPD in July
Clinical trial start
expected 2H 2022
Pan-SARS-CoV-2 vaccine candidate
Potential for greater, more durable
protection to manage future variants
of concern
Proof-of-concept trial
expected 2H 2022
Long-term strategy comprises multipronged approach designing and testing multiple constructs with the aim
to engage different arms of the immune system including antibodies and T cells
BIONTECHView entire presentation